Literature DB >> 12895525

Potential role of the cannabinoid receptor CB1 in rapid eye movement sleep rebound.

L Navarro1, M Martínez-vargas, E Murillo-rodríguez, A Landa, M Méndez-díaz, O Prospéro-garcía.   

Abstract

Sleep is an unavoidable activity of the brain. The delay of the time to sleep (sleep deprivation), induces an increase of slow-wave sleep and rapid-eye-movement (REM) sleep (rebound) once the subject is allowed to sleep. This drive to sleep has been hypothesized to be dependent on the accumulation of sleep-inducing molecules and on the high expression of these molecule receptors. In this study we selectively deprived rats of REM sleep for 24 h by using the flowerpot technique. One group deprived of REM sleep was treated with SR141716A, a cannabinoid receptor 1 (CB1) receptor antagonist and then allowed to sleep for the next 4 h. Two other groups were killed, one immediately after the REM sleep deprivation period and the other after 2 h of REM sleep rebound (REM sleep deprivation plus 2 h of rebound). In both groups we determined the expression of the CB1 receptor and its mRNA. Results indicated that SR141716A prevents REM sleep rebound and REM sleep deprivation does not modify the expression of the CB1 protein or mRNA. However, REM sleep deprivation plus 2 h of sleep rebound increased the CB1 receptor protein and, slightly but significantly, decreased mRNA expression. These results suggest that endocannabinoids may be participating in the expression of REM sleep rebound.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895525     DOI: 10.1016/s0306-4522(03)00339-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Authors:  Laura H Jacobson; S Renee Commerford; Sarah P Gerber; Yu Alice Chen; Beatriz Dardik; Frederique Chaperon; Chad Schwartzkopf; Van Nguyen-Tran; Thomas Hollenbeck; Peter McNamara; Xiaohui He; Hong Liu; H Martin Seidel; Anne-Liese Jaton; Jesper Gromada; Sandra Teixeira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.

Authors:  Michael W Calik; David W Carley
Journal:  Sleep       Date:  2017-09-01       Impact factor: 5.849

Review 4.  The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products.

Authors:  Jinpeng Li; Ricardo Carvajal; Leon Bruner; Norbert E Kaminski
Journal:  Food Chem Toxicol       Date:  2021-10-06       Impact factor: 5.572

Review 5.  Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.

Authors:  Maureen L Petrunich-Rutherford; Michael W Calik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Additive effect of 5-HT2C and CB1 receptor blockade on the regulation of sleep-wake cycle.

Authors:  Emese Bogáthy; Noémi Papp; Laszló Tóthfalusi; Szilvia Vas; György Bagdy
Journal:  BMC Neurosci       Date:  2019-03-20       Impact factor: 3.288

7.  Multiple sleep alterations in mice lacking cannabinoid type 1 receptors.

Authors:  Alessandro Silvani; Chiara Berteotti; Stefano Bastianini; Viviana Lo Martire; Roberta Mazza; Uberto Pagotto; Carmelo Quarta; Giovanna Zoccoli
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.